Medicine and technology can work together to produce amazing results. One of the most promising ‘marriages’ is that involving stem cell research and artificial intelligence (AI). Researchers are attempting to use AI to aid and augment stem cell technologies. How can machine learning play a role in restorative medicine? [Read more…]
Promising Drugs, Antibodies, and Vaccines in Development Against COVID-19
What are the most promising drugs, antibodies, and vaccines in development against COVID-19? Our team sifted through hundreds of articles and research papers to identify the most promising ones. In most cases, these drugs, vaccines and antibodies are already in use for other diseases, making it easier to leverage them in the fight against the Coronavirus. [Read more…]
AlloVir & Baylor College of Medicine to Develop Allogeneic T-Cell Therapies for COVID-19
AlloVir’s proprietary technology is designed to develop virus specific T-cell therapies with potential to treat and prevent several devastating viral diseases with each single cell therapy product.
CAMBRIDGE, Mass & HOUSTON- AlloVir, a late-clinical stage T-cell immunotherapy company, today announced the expansion of its research and development collaboration with Baylor College of Medicine to include the discovery and development of allogeneic, off-the-shelf, virus specific T-cell therapies to combat SARS-CoV-2, the virus that causes COVID-19. [Read more…]
Lattice Biologics Launches Phase 1 Coronavirus Trial in Seattle for AmnioBoost Stem Cell Therapy
Lattice Biologics is recruiting 10 patients for it Phase 1 clinical trial in Seattle to assess its novel stem cell therapy, AmnioBoost, for the treatment of COVID-19 lung disease.
BELGRADE, Mont. — Lattice Biologics Ltd. has begun enrolling patients in its Phase 1 clinical trial to address safety and efficacy of its novel stem cell technology, AmnioBoost, for the treatment of severe acute respiratory syndrome (SARS) related to COVID-19 infection. AmnioBoost is derived from amniotic fluid taken from non-related, healthy, living donors during a Caesarian delivery. The baby is not harmed in any way. [Read more…]
Celltex Plans to Launch Program to Use MSCs for COVID-19-related Symptoms Under an Existing Regulatory Study
March 16, 2020, HOUSTON– Celltex Therapeutics Corporation, a Houston, Texas-based biotechnology company founded in 2011 and focused on spearheading breakthroughs in regenerative medicine using adult, autologous Mesenchymal Stem Cells (“MSCs”), today announced that it has begun active discussions with the FDA regarding a study using MSCs against Coronavirus (“COVID-19”)-type symptoms. [Read more…]
- « Previous Page
- 1
- …
- 199
- 200
- 201
- 202
- 203
- …
- 338
- Next Page »